Viridian Therapeutics

WALTHAM, MA · Founded 2020 · Biotech · Public

Optimized monoclonal antibodies for rare autoimmune diseases

Claim this profile

Follows are private to you and power your alerts

Updated · viridiantx.com

Sector
Biotech
Headquarters
WALTHAM, MA
Founded
2020
Latest Form D
$27M, Sep 2020
Total capital
$29M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$29M
2 Form D · last Sep 2020
73 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
5
35 pending · first 2023
Rank in peer group#269 of 1449

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $29M1st Form D$2M2nd Form D$27M
2020FEDERAL ↑EQUITY ↓Cumulative $29M1st Form D$2M2nd Form D$27M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$27M
  • Private capital raisedForm D · SEC · 1st filing$2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#269 · top 19%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Jonathan ViolinExecutive Officer, DirectorNamed in SEC Form D filings
  • Peter HarwinDirectorNamed in SEC Form D filings
  • Tomas KiselakDirectorNamed in SEC Form D filings

What it has protected

USPTO · 5 granted of 40
Show all 40 patent records
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseAug 27, 2026 · Application 19287281Pending
  • Methods Of Treating Chronic Thyroid Eye DiseaseMay 14, 2026 · Application 19442626Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApr 14, 2026 · US 12,600,788Granted
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApr 7, 2026 · US 12,595,309Granted
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 9, 2025 · Application 19242715Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseSep 2, 2025 · US 12,404,337Granted
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseSep 2, 2025 · US 12,404,335Granted
  • Fcrn Antagonists With Improved Half-life And Methods Of UseMay 15, 2025 · Application 18917838Pending
  • Pharmaceutical Compositions Of ANTI-IGF-1R AntibodiesMar 27, 2025 · Application 18827383Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 31, 2024 · Application 18760539Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 24, 2024 · Application 18749821Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseOct 17, 2024 · Application 18760575Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseFeb 8, 2024 · Application 18364620Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseMar 16, 2023 · Application 17818798Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseJan 10, 2023 · US 11,548,951Granted
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseSep 1, 2022 · Application 17724639Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseAug 25, 2022 · Application 17501430Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseAug 25, 2022 · Application 17501362Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseJul 28, 2022 · Application 17450872Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63656371Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63619034Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63619028Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63619033Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63611151Pending
  • Methods Of Treating Active And Chronic Thyroid Eye DiseaseApplication 63512468Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2023060207Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2023060206Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2022082214Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2022074764Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63266549Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63266548Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63293242Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2021054914Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication PCTUS2021054907Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63261744Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63261742Pending
  • Compositions, Doses, And Methods For Treatment Of Thyroid Eye DiseaseApplication 63260133Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63260130Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63201978Pending
  • Compositions And Methods For Treatment Of Thyroid Eye DiseaseApplication 63091839Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .